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Abstract
Optimal antithrombotic management of atrial fibrillation equals balancing between prevention of arterial thromboembolism,
predominantly ischaemic stroke, and haemorrhagic complications. Over time different antithrombotic agents and strategies
have been developed. At present, non-vitamin K antagonist oral anticoagulants (NOACs) are the first-line therapy for stroke
prevention in patients with non-valvular atrial fibrillation (i.e. without a mechanical valve prosthesis or rheumatic heart
disease). Considering the impact of the suboptimal adoption of recommended oral anticoagulant therapy, as experienced
with the previous first-line vitamin K antagonists, this review focuses on adequate use of NOACs. As such, we address
the most important and clinically challenging issues in the antithrombotic life cycle management for long-term stroke
prevention in atrial fibrillation.
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Introduction
Ischaemic stroke is probably the most infamous compli-
cation of non-valvular atrial fibrillation (AF). Untreated,
the average annual stroke risk is 5% and exceeds 7% if
clinically undetected strokes and transient ischaemic at-
tacks (TIAs) are taken into account [1]. These observa-
tions triggered an ongoing search for the optimal antithrom-
botic strategy: a practical approach for maximum stroke and
bleeding risk reduction. Anno 2018, this strategy consists of
1) AF documentation, 2) long-term stroke risk assessment
using the CHA2DS2-VASc score (congestive heart failure,
hypertension, age ≥75 years [doubled], diabetes mellitus,
prior stroke [doubled], vascular disease, age 65–74 years
and female sex), 3) modifiable stroke and bleeding risk
factor identification and 4) appropriate initiation of a non-
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vitamin K antagonist oral anticoagulant (NOAC), unless
contra-indicated [2].
The above-mentioned integrated AF treatment approach
appears simple and straightforward and appropriate use re-
sults in a very substantial stroke and mortality reduction.
However, inappropriate use or deprivation of patients from
an effective strategy may lead to suboptimal clinical out-
come. The latter is one specific lesson learned from the vi-
tamin K antagonist (VKA) era [3]. This review focuses on
adequate use of NOACs to prevent history from repeating
itself. As such, we address the most important and clinically
challenging issues in antithrombotic life cycle management
for long-term stroke prevention in AF (Fig. 1).
Initiation of long-term antithrombotic
management
AF documentation and indication for oral
anticoagulation (OAC)
Given the significant antithrombotic therapeutic conse-
quences and their potential sequelae, it all starts with
unequivocal electrocardiographic documentation of AF.
Next, identifying clinical AF duration and type, adequate
treatment of symptoms, underlying cardiovascular and pul-
monary disease and/or other triggers. However, it is worth
noting that the indication for OAC is independent of the
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KEY MESSAGE
The ideal follow-up strategy for patients using NOACs should include monitoring to avoid 
under- and overdosing. This includes assessment of renal function, body weight, and 
modifiable bleeding risk factors.  Other important aspects are education, of both patient 
and physician, and interdisciplinary communication.
type of AF. A clinically challenging scenario is the patient
with secondary AF: a paroxysmal episode only documented
during a temporary, reversible disease state (e.g. thyrotox-
icosis, post-operative inflammation, and infections such
as pneumonia). These patients have both a higher risk of
‘future’ AF and worse long-term cardiovascular outcomes
[4]. However, optimal long-term antithrombotic manage-
ment of secondary AF remains unclear in the absence of
randomised controlled trials (RCTs). Despite the associa-
tion of OAC use with reduced long-term mortality in post-
operative AF patients [4], appropriate risk assessment, tim-
ing and patient preference need to be taken into account.
Currently, the same accounts for atrial sensing of asymp-
tomatic high atrial rate episodes by implantable devices.
There is supporting evidence that the majority of these
patients with ‘subclinical AF’ also have an increased stroke
risk [5, 6], it is still unclear whether and when they benefit
from OAC, also considering the bleeding risk. OAC has to
be considered in patients with two additional CHA2DS2-
VASc risk factors (i.e. ≥2 in males, ≥3 in females) and
an AF burden >24h (if there are no contraindications) [7].
Lower duration may merit OAC if multiple risk factors are
present.
Short-term stroke risk
Somewhat artificially we can differentiate a short- and long-
term stroke risk. The former has a different, more ‘mechan-
ical’ pathophysiology. Functional left atrial (appendage)
standstill during AF is followed by resolution of atrial stun-
ning upon sinus rhythm restoration [8]. This mechanism is
thought to be responsible for the post-cardioversion strokes,
nearly all occurring within 10 days after cardioversion [9].
This relates to the known proportional relationship between
the duration of the AF episode and the time until normal
atrial contraction returns [8, 10]. Similarly, there is a risk
of peri-ablation left atrial appendage thrombus. The opti-
mal management of this short-term stroke risk is a separate
entity and depends on the planned procedure, i.e. cardiover-
sion or ablation.
Long-term stroke risk assessment
The vascular nature of AF is underlined by the high preva-
lence of cardiovascular co-morbidities, which represent
the intrinsic long-term stroke risk. The most important
independent stroke risk factors are incorporated into the
CHA2DS2VASc score and its use is recommended for
stroke risk assessment in AF patients [2]. Considering the
increasing aging of our society it is important to emphasise
that age is an extremely strong, continuous, risk factor for
stroke [11] and aging potentiates other risk factors such as
heart failure. Therefore, the CHA2DS2VASc score should
be reassessed over time [12]. Untreated, one out of every
four octogenarians with AF suffers a stroke during their
remaining lifetime [1]. Still, across various health care set-
tings studies demonstrated age, frailty and dementia to be
some of the strongest independent predictors of withhold-
ing anticoagulation in the eldest elderly [13–15]. However,
in these patients the key question is not whether, but how
we should organise optimal anticoagulation.
Major bleeding risk assessment
The downside of any antithrombotic drug is an increase
of patients’ intrinsic risk of bleeding. It therefore makes
sense to identify bleeding risk factors. Practical bleeding
risk scores, such as HASBLED [16], assist in particular
with identifying modifiable risk factors. Thereby minimis-
ing the risk of major bleeding during OAC treatment. How-
ever, we should keep in mind that the available risk scores
fail to capture important frailty aspects in the eldest elderly
with AF [17] and, similarly in elderly with venous throm-
boembolism [13]. Here, previous reports demonstrated that
age itself proved to be a strong determinant of risk. Espe-
cially the eldest elderly (85+) appear to have a substantial
increased risk of major bleeding [18, 19]. This enhanced
bleeding risk also applies for patients with a poor qual-
ity of anticoagulation (i.e. time in therapeutic range [TTR]
<65%, patients spent a median 14%, 71%, and 15% of time
below, within, and above the intended therapeutic range, re-
spectively) [20].
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Fig. 1 Oral anticoagulation
life-cycle management in atrial
fibrillation
Table 1 Preconditions for effective shared decision making
Motivation Communication Infrastructure
Willingness Stroke risk and
impact
ICT support
Social support Bleeding risk and
impact
Substitution of care
Cognitive capability On a patient level Time
Choosing anticoagulation: shared decisionmaking
According to the current European Society of Cardiology/
European Heart Rhythm Association (ESC/EHRA) guide-
lines men and women with a CHA2DS2VASc score of 2
and 3, respectively, clearly benefit from OAC. In case of
a CHA2DS2VASc score of 1 in men and 2 in women, OAC
is likely to provide net clinical benefit and individual char-
acteristics and patients’ preferences should be considered
[2]. However, a primary care study among 260 AF patients
aged 70–85 years that used decision analysis regarding
antithrombotic treatment preference showed that approxi-
mately half of the patients with a preference for OAC did
not receive it [21]. On the other hand, 47% of patients
were not being prescribed warfarin although the results of
their decision analysis suggested they wanted to be. A re-
searcher-administered questionnaire study using a fictional
AF patient and pictograms to display the 10-year risk of
stroke showed that 100% of the elderly chose OAC over
no treatment. However, when the necessity of many tablets
with multiple blood tests, alcohol restrictions and an in-
creasing risk of intracranial haemorrhage was introduced,
the choice for anticoagulation dropped. A daily tablet cor-
responds to 94%, an intracranial haemorrhage risk of 0.1%/
year corresponds to 99% and 0 units of alcohol/day corre-
sponds to 89% who would still choose OAC [22]. Although
most physicians will acknowledge its importance, practical
and evidence-based methods of shared decision making in
AF patients are an unmet need (Table 1).
Choosing anticoagulation: aspirin is no suitable
alternative
The downside of any antithrombotic drug is the increase
of the patients’ intrinsic bleeding risk. Undeniably, fear for
bleeding has caused physicians to choose aspirin over VKA
for perceived lower bleeding risk. However, it is important
to realise that there is no relationship between a drug’s
ability to prevent stroke and its potential to harm through
bleeding (safety paradox). In fact, irrespective of age, as-
pirin use in AF patients is associated with a similar rate
of major bleeding events compared with VKA but with
significantly inferior stroke protection [23, 24]. This also
holds true for the eldest elderly (n= 366≥ 85 years): as-
pirin vs. apixaban, 4.9% vs. 4.7% major bleeding events
and 7.5% vs. 1.0% strokes, respectively, per year in one
study [19]. Furthermore, the combination of aspirin with
clopidogrel also provides inferior stroke protection in AF
patients compared with VKA [25]. Finally, OAC is the only
antithrombotic regimen that reduces all-cause death [26].
Thus, even in AF patients with a low stroke risk (i.e.
CHA2DS2VASc score <2 in men and <3 in women), aspirin
is not a suitable alternative, it warrants either no antithrom-
botic therapy or OAC [2]. However, we should keep in mind
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Paent characteriscs Dabigatran Rivaroxaban Apixaban Edoxaban 
A. Dosing     
Renal insuﬃciency - dose adjust (CrCl) 30-50 15-50 15-30 15-50 
Body weight - dose adjust (kg)       <60 
Age - dose adjust (years) >80       
Other or mulple factors - dose adjust a    b  c  
B. Choosing     
Mechanical valve prosthesis  
Renal insuﬃciency (CrCl) <30 <15 <15 <15 
Risk of drug-drug interacon Check interacon data/if not available: avoid NOAC 
Preference for once daily     
Gastrointesnal bleeding risk [?PPI] 150 mg^    
Compable with use in medicaon roll     
Andote  Andote currently under invesgaon 
Orange: acon mandatory, or avoid speciﬁc NOAC 
Red: NOAC contra-indicated 
Yellow: cauon in case of other interfering factors, check EMEA/SmPC (i.e. drug interacon, increased bleeding risk) 
Fig. 2 Dosing (A) and choosing (B) a NOAC in atrial fibrillation. The proposals voiced here are not based on head to head comparisons of the four
NOACs but are derived from European labelling (EMA, and related SmPCs) and current ESC guidelines on AF. AF atrial fibrillation, BID twice
daily, CrCl creatinine clearance, EMA European Medicines Agency, ESC European Society of Cardiology, NOAC non-vitamin K antagonist oral
anticoagulant, P-gp P-glycoprotein, SmPC summary of product characteristics, aVerapamil, bIf 2 out of 3: age ≥80 years, weight 60kg, serum
creatinine ≥133µmol/L cStrong P-gp inhibitor (excluding verapamil), check EMEA/SmPC, dPPI Consider proton pump inhibitor, ePreference for
110mg BID in case of gastritis/oesophagitis
that these patients may require aspirin for the prevention of
other atherosclerotic complications.
Choosing anticoagulation: NOACs
The collaborative evidence from multiple, large clinical
trials randomising elderly AF patients to a NOAC or VKA
consistently demonstrated at least similar efficacy and
safety, but significantly less intracranial haemorrhage with
all NOACs compared with VKA [2]. In addition, compared
with VKAs, NOACs are much easier to use with a rapid
onset and offset (comparable with low-molecular-weight
heparins), standard daily dosing (no need for frequent rou-
tine blood tests) and limited drug interactions. Therefore,
NOACs are the current first-line oral anticoagulant in the
absence of a contra-indication [2].
NOACs are only contra-indicated in the infrequent
case of, usually rheumatic, moderate/severe mitral steno-
sis, end-stage renal disease, or mechanical heart valves.
These subgroups were excluded from the NOAC trials.
Furthermore, the thromboembolic pathophysiology in both
rheumatic valve disease [1] and mechanical heart valves is
significantly different. For now, in the case of the above-
mentioned groups VKAs are indicated.
In the absence of head-to-head randomised controlled
trials there is no superior NOAC. The value of these drugs
lies in the significant benefits over VKAs and aspirin as
discussed above. Still, nuances between the respective land-
mark trials (e.g. baseline stroke risk factors, age, the occur-
rence of side effects), practical aspects (e.g. once vs. twice
daily, tablet/capsule size, blister packaging, antidote) and
pharmacokinetics (e.g. reduced renal function, drug inter-
actions) allow for choice (Fig. 2). Furthermore, the prescrib-
ing physician’s experience with and preference for specific
NOACs should play a role in this choice.
Of much greater importance is choosing the appropriate
NOAC dose in order to replicate RCT results in daily clin-
ical practice and pursue optimal stroke protection (Fig. 2).
This seems logical, but ‘real-world’ data consistently show
label-discordant dosing, in particular an inappropriately
lower dose [27–32]. Although the reasons remain specu-
lative, it could be because of a perceived increased risk
of bleeding. However, physicians should be aware of the
safety paradox: inappropriate low dosing results in poten-
tially preventable strokes [33, 34], not significantly fewer
major bleeding events [33, 35]. In order to appropriately
dose NOACs the relevant criteria must be checked. Renal
function is important for all NOACs, but information about
recent renal function was lacking in a third of the AF
patients in a large international prospective NOAC reg-
istry [32]. This calls for nationwide prospective registries,
such as DUTCH-AF (Project number 848050006, ZonMw-
programma Goed Gebruik Geneesmiddelen).
Aspects of successful long-term
antithrombotic management
Long-term antithrombotic management does not stop fol-
lowing the OAC and NOAC prescription. The ideal follow-
up strategy for patients using NOACs is unclear. It should
include monitoring to avoid under- and overdosing. In addi-
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Table 2 Registered randomised clinical trials on long-term antithrombotic management of atrial fibrillation
Trial number Start End Title Acronym n
NCT02928133 04.2014 05.2018 NOACs for Atrial Tachyarrhythmias in Congenital Heart Dis-
ease
NOTE 300
NCT01994265 10.2014 05.2018 Cognitive Impairment Related to Atrial Fibrillation Prevention
Trial
GIRAF 200
NCT02941978 12.2015 05.2018 Motivational Interviewing to Support Oral AntiCoagulation
Adherence in Patients With Non-valvular Atrial Fibrillation
MISOAC-AF 1000
NCT02690649 01.2016 06.2018 Keep it SIMPLE: Improving Anti-Coagulation Medication
Adherence
250
NTR5532 01.2016 08.2018 Management of Atrial fibriLLation INcluding tailoring of anti-
coagulation in patients from primary care
ALL-IN 1000
NCT03174093 06.2017 11.2018 Mhealth Application for anTicoagulation Care in Atrial MATCh AFib 200
NCT02889562 09.2016 12.2018 Apixaban Versus Warfarin for the Management of Post-opera-
tive Atrial Fibrillation
56
NCT02666157 01.2016 12.2018 Comparison of Efficacy and Safety Among Dabigatran, Ri-
varoxaban, and Apixaban in Non-Valvular Atrial Fibrillation
DARING-AF 3672
NCT02933697 04.2017 04.2019 Compare Apixaban and Vitamin-K Antagonists in Patients With
Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
AXADIA 222
NCT02618577 02.2016 05.2019 Non-vitamin K Antagonist Oral Anticoagulants in Patients With
Atrial High Rate Episodes
NOAH 3400
NCT02942407 12.2016 05.2019 Trial to Evaluate Anticoagulation Therapy in Hemodialysis
Patients With Atrial Fibrillation
RENAL-AF 762
NCT03126214 05.2017 09.2019 Improving Stroke Prevention in Atrial Fibrillation Through
Pharmacist Prescribing
PIAAF Rx 370
NCT02998905 04.2017 01.2020 NOACs for Stroke Prevention in Patients With Atrial Fibrilla-
tion and Previous ICH (NASPAF-ICH)
NASPAF-ICH 100
NCT02426944 04.2015 05.2020 Left Atrial Appendage Closure vs. Novel Anticoagulation
Agents in Atrial Fibrillation
PRAGUE-17 400
NCT02961348 02.2017 12.2020 TIMING of Oral Anticoagulant Therapy in Acute Ischemic
Stroke With Atrial Fibrillation
3000
NCT02387229 03.2015 02.2021 Blinded Randomized Trial of Anticoagulation to Prevent Is-
chemic Stroke and Neurocognitive Impairment in AF
BRAIN-AF 6396
NCT03061006 04.2017 04.2021 Impact of Anticoagulation Therapy on the Cognitive Decline
and Dementia in Patients With Non-Valvular Atrial
CAF 120
NCT01938248 05.2015 04.2021 Apixaban for the Reduction of Thrombo-Embolism in Patients
With Device-Detected Sub-Clinical Atrial Fibrillation
ARTESiA 4000
NCT03148457 07.2017 07.2021 Early Versus Late Initiation of Direct Oral Anticoagulants in
Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN):
an International, Multicentre, Randomised-controlled, Two-arm,
Assessor-blinded Trial
ELAN 2000
NCT03021928 06.2017 08.2021 Optimal Delay Time to Initiate Anticoagulation After Ischemic
Stroke in Atrial Fibrillation
START 1000
NCT03129490 04.2017 09.2021 The Danish Non-vitamin K Antagonist Oral Anticoagulation
Study in Patients With Atrial Fibrillation
DANNOAC-AF 11000
NCT02168829 01.2016 12.2021 Optimal Anticoagulation for Higher Risk Patients Post-Catheter
Ablation for Atrial Fibrillation Trial
OCEAN 1452
NCT02886962 01.2017 01.2023 Oral Anticoagulation in Haemodialysis Patients AVKDIAL 6396
NCT02928497 02.2017 12.2023 Assessment of the WATCHMAN™ Device in Patients Unsuit-
able for Oral Anticoagulation
ASAP-TOO 888
NCT02830152 05.2017 05.2030 Prevention of Stroke by Left Atrial Appendage Closure in
Atrial Fibrillation Patients After Intracerebral Hemorrhage
750
NCT02565693 09.2014 Apixaban Versus Antiplatelet Drugs or no Antithrombotic
Drugs After Anticoagulation-associated Intracerebral Haem-
orrhage in Patients With Atrial Fibrillation
APACHE-AF 100
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Fig. 3 Prescription rates of non-vitamin K antagonist oral anticoagulants (a) and vitamin K antagonists (b) in the Netherlands
tion, periodic assessment of modifiable bleeding risk factors
and renal function seems appropriate because it matters for
safety and/or dose recommendation for all NOACs. Another
important aspect is education, of both patient and physician,
and interdisciplinary communication. There appears to be
room for improvement [36] as suggested by the outcome
from a recent cluster RCT investigating an educational in-
tervention program [37]. Of the 371 control group patients
with a long-term indication for OAC only 5.9% was aware
of medical emergencies (e.g. melena or signs suggestive of
stroke). Knowledge was also scarce regarding what anal-
gesics are safest to use (15.4%), what to do after a missed
dose (19.9%), when to inform others about their OAC use
(23.9%) and target international normalised ratio (45.5%)
[37]. On the upside, the educational intervention signifi-
cantly increased the knowledge level which sustained up to
24 months in that study [37].
Antithrombotic management following major
bleeding and stroke
As pointed out by Maikranz et al. [37] it appears that very
few patients with long-term OAC know how to act in case of
unexpected major bleeding events. However, it is important
to realise (and communicate) that these major events occur
despite optimal preventive measures and to discuss with the
patient how to act.
A predominantly upper gastrointestinal bleeding is the
most frequent major bleeding complication in patients us-
ing long-term antithrombotic treatment, both aspirin and
OAC [38]. Although gastrointestinal bleeding in itself is
often non-fatal, it is a prognostic marker as reflected by
a death rate of 30–35% in two years following the index
event [39, 40]. Restarting OAC following a gastrointestinal
bleeding is the only regimen associated with both a very sig-
nificant reduction of all-cause mortality [39–43] and stroke.
Although the risk of major bleeding increases with reini-
tiating OAC, the risk of a recurrent gastrointestinal bleed
does not [39, 40], except in patients with end-stage renal
disease [43]. In case of repetitive gastrointestinal bleeding,
quality of life also plays an important role in the shared de-
cision to whether or not restart OAC therapy. Furthermore,
it is important to take the potential mechanism into account.
For instance, esophagogastroduodenoscopy confirmed ulcer
healing before initiation of OAC significantly reduces the
rate of major bleeding [44]. Also, good (>65%) opposed
to poor (<65%) TTR did not increase the risk of a recur-
rent ulcer bleeding but provided better stroke prevention
[42]. The optimal time window of reinitiating OAC follow-
ing gastrointestinal bleeding remains unclear. Qureshi et al.
found that restarting OAC seven compared with thirty days
after a gastrointestinal bleeding did not increase the risk of
major bleeding but was associated with lower mortality and
stroke rates [39].
Regarding the most feared and fatal bleeding complica-
tion, intracranial haemorrhage, a Danish nationwide study
revealed that AF patients who survived the initial six weeks
following an intracranial haemorrhage had a substantial re-
duction of all-cause mortality and stroke compared with no
OAC during one-year follow-up (hazard ratio 0.55, confi-
dence interval 0.39–0.78) [45]. A Swedish nationwide study
showed that of the surviving 1,454 patients of a first in-
tracranial haemorrhage under OAC, 10.4% resumed OAC
within three and 21.2% within twelve months [46]. Oral
anticoagulants should probably not be resumed in patients
with a lobar intracerebral haemorrhage caused by cerebral
amyloid angiopathy, given the high risk (3–14% within one
year) of recurrent intracranial haemorrhage [47]. Although
RCTs answering the question whether and when to resume
antithrombotic medication in patients who suffered an in-
Neth Heart J (2018) 26:311–320 317
Fig. 4 Reporterd side-effects of
non-vitamin K antagonist oral
anticoagulants (a) and vitamin K
antagonists (b) in the Nether-
lands (a Source: www.lareb.
nl; updated 4.7.17. At this mo-
ment in time too few side-effects
regarding edoxaban were re-
ported to portrait a breakdown.,
b Source: www.gipdatabank.nl;
updated 22.11.16)
tracranial haemorrhage are lacking, one is currently recruit-
ing in the Netherlands (APACHE AF trial) (Table 2). Hence,
resuming antithrombotic medication should be a multidis-
ciplinary decision, involving a cardiologist, neurologist and
a geriatric specialist or general practitioner [48].
Early stroke recurrence of cardioembolic origin is as high
as 14% within two weeks. OAC substantially reduces this
risk. Even, or perhaps especially, the eldest elderly benefit
as Appelros et al. demonstrated a reduced all-cause mor-
tality and stroke rate in nonagenarians (between 90 and
100 years of age) [49]. Initiation of OAC monotherapy,
which outperforms low-molecular-weight heparin alone or
followed by OAC, 4–14 days following the index stroke op-
posed to outside this window provides the best protection
against recurrent stroke [50]. Perhaps beside the use of the
National Institutes of Health stroke severity scale [2], the
novel ALESSA score might assist in deciding upon early
initiation or re-initiation [51].
Side effects could trigger incorrect or non-use of OAC
leading to a vicious circle. It therefore deserves spe-
cial attention during follow-up. However, it seems as if
a magnifying glass is being held over the side effects of
NOACs as reflected by the registration in the Netherlands
(Lareb). Interestingly, the industry filed most (35%) of the
reports followed by patients (17–20%) and pharmacists
(16%), whereas physicians (8%) provided the least of the
reports. In the Netherlands, rivaroxaban and dabigatran
became available in 2011, followed by apixaban (2013)
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and edoxaban (2015) (Fig. 3a). Since then, the Netherlands
pharmacovigilance centre Lareb received a total of 1,487
(609 were severe) side effect notifications among 84,047
NOAC users. A NOAC specific breakdown is displayed in
Fig. 4a. During the same time period (2011-present) among
the >400,000 VKA users (Fig. 3b) Lareb received a total
of 1,237 (366 were severe) side effect reports (Fig. 4b).
Perhaps, this provides food for thought on how we can
optimise the monitoring and reporting of long-term side
effects in the near future. Furthermore, results of real-life
studies and registries are instrumental in understanding
how new therapies find their way in daily clinical practice
and for the identification of pitfalls.
Several ongoing and future trials will also provide an-
swers on current knowledge gaps (Table 2).
End of long-term antithrombotic
management
The rate of OAC use only declines despite an increasing
risk of stroke over time [11, 52]. Until recently this was
partly driven by the fact that there was no suitable alterna-
tive for VKA treatment. Many of the previously discussed
aspects such as patient education, frailty, reduced life ex-
pectancy, stroke, major bleeding or drug specific side effects
contribute to the withholding or permanent discontinuation
of OAC. In the contemporary RCTs permanent OAC dis-
continuation was roughly 20% in two years, with a higher
rate of cessation in the first year of follow-up. Permanent
discontinuation occurred significantly more with dabigatran
and significantly less with apixaban compared with warfarin
and aspirin [24, 53, 54]. In ‘real life’, permanent discon-
tinuation can be as low as 20% in five years, even in the
VKA-naive eldest elderly [55]. Despite the previously dis-
cussed superior reduction of all-cause mortality and stroke,
in selected patients OAC is permanently discontinued after
a careful shared decision process, similar to deactivating
the defibrillator capacity of the ICD. However, literature to
support best practice on this topic is lacking.
Conclusions
Current clinical knowledge and evidence concerning opti-
mal long-term antithrombotic management of AF patients
provide clear recommendations for the majority of patients.
However, a relentless suboptimal use of OAC remains a ma-
jor concern, especially in the elderly. Several ongoing RCTs
aim to fill ‘the knowledge gap’ in specific patient groups or
situations concerning the start, continuation or discontinu-
ation of OAC. Still, important unmet needs are improved
education, guidance on shared decision making [56], as-
sessment and impact of frailty, and prospective registries of
daily clinical practice, such as DUTCH-AF (Project number
848050006, ZonMw-programma Goed Gebruik Geneesmid-
delen).
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